Difference between revisions of "Copanlisib (Aliqopa)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplasti...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. | From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. | ||
| + | |||
| + | ==Preliminary data== | ||
| + | ===[[Follicular lymphoma]]=== | ||
| + | # '''Abstract:''' Martin H. Dreyling, Armando Santoro, Sirpa Leppa, Judit Demeter, George Follows, Georg Lenz, Won Seog Kim, Luigina Mollica, Arnon Nagler, Colin Phipps Diong, Mariano Provencio, Don A. Stevens, David Trevarthen, Massimo Magagnoli, Lisa Cupit, Shuxin Yin, Florian Hiemeyer, Jose E. Garcia-Vargas, Barrett H. Childs, and Pier Luigi Zinzani. Copanlisib in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology 2017 35:15_suppl, 7535-7535 [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7535 link to abstract] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 7: | Line 11: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:PI3K inhibitors]] | [[Category:PI3K inhibitors]] | ||
| + | |||
| + | [[Category:Follicular lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 13:43, 12 June 2017
Mechanism of action
From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Preliminary data
Follicular lymphoma
- Abstract: Martin H. Dreyling, Armando Santoro, Sirpa Leppa, Judit Demeter, George Follows, Georg Lenz, Won Seog Kim, Luigina Mollica, Arnon Nagler, Colin Phipps Diong, Mariano Provencio, Don A. Stevens, David Trevarthen, Massimo Magagnoli, Lisa Cupit, Shuxin Yin, Florian Hiemeyer, Jose E. Garcia-Vargas, Barrett H. Childs, and Pier Luigi Zinzani. Copanlisib in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology 2017 35:15_suppl, 7535-7535 link to abstract